Department and Institute of Psychiatry, Universidade de São Paulo Medical School, R. Dr. Ovídio Pires de Campos, s/n, 3. andar, São Paulo, SP, 05403-010, Brazil.
Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.
Few case series studies have addressed the issue of treatment response in patients with obsessive-compulsive disorder (OCD) and comorbid post-traumatic stress disorder (PTSD), and there are no prospective studies addressing response to conventional treatment in OCD patients with a history of trauma (HT). The present study aimed to investigate, prospectively, the impact of HT or PTSD on two systematic, first-line treatments for OCD. Two hundred and nineteen non-treatment-resistant OCD outpatients were treated with either group cognitive-behavioral therapy (GCBT n = 147) or monotherapy with a selective serotonin reuptake inhibitor (SSRI n = 72). Presence of HT and PTSD were assessed at intake, as part of a broader clinical and demographical baseline characterization of the sample. Severity and types of OCD symptoms were assessed with the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and the Dimensional YBOCS (DYBOCS), respectively. Depression and anxiety symptoms were measured with the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Both treatments had 12-week duration. Treatment response was considered as a categorical [35% or greater reduction in baseline YBOCS scores plus a Clinical Global Impression-Improvement rating of better (2) or much better (1)] and continuous variable (absolute number reduction in baseline YBOCS scores). Treatment response was compared between the OCD + HT group versus the OCD without HT group and between the OCD + PTSD group versus the OCD without PTSD group. Parametric and non-parametric tests were used when indicated. Data on HT and PTSD were available for 215 subjects. Thirty-eight subjects (17.67% of the whole sample) had a positive HT (OCD + HT group) and 22 subjects (57.89% of the OCD + HT group and 10.23% of the whole sample) met full DSM-IV criteria for PTSD. The OCD + HT and OCD without HT groups presented similar response to GCBT (60% of responders in the first group and 63% of responders in the second group, p = 1.00). Regarding SSRI treatment, the difference between the response of the OCD + HT (47.4%) and OCD without HT (22.2%) groups was marginally significant (p = 0.07). In addition, the OCD + PTSD group presented a greater treatment response than the OCD without PTSD group when treatment response was considered as a continuous variable (p = 0.01). The age when the first trauma occurred had no impact on treatment response. In terms of specific OCD symptom dimensions, as measured by the DYBOCS, OCD treatment fostered greater reductions for the OCD + PTSD group than for the OCD without PTSD group in the scores of contamination obsessions and cleaning compulsions, collecting and hoarding and miscellaneous obsessions and related compulsions (including illness concerns and mental rituals, among others). The OCD + PTSD group also presented a greater reduction in anxiety scores than the OCD without PTSD group (p = 0.003). The presence of HT or PTSD was not related to a poorer treatment response in this sample of non-treatment-resistant OCD patients. Unexpectedly, OCD patients with PTSD presented a greater magnitude of response when compared with OCD without PTSD patients in specific OCD symptom dimensions. Future studies are needed to clarify if trauma and PTSD have a more significant impact on the onset and clinical expression of OCD than on the conventional treatment for this condition, and whether OCD stemming from trauma would constitute a subtype of OCD with a distinct response to conventional treatment.
目前鲜有研究探讨合并创伤后应激障碍(PTSD)的强迫症(OCD)患者的治疗反应问题,也没有前瞻性研究针对有创伤史(HT)的 OCD 患者常规治疗的反应。本研究旨在前瞻性地研究 HT 或 PTSD 对两种系统的 OCD 一线治疗的影响。219 名非难治性 OCD 门诊患者接受了团体认知行为疗法(GCBT,n=147)或选择性 5-羟色胺再摄取抑制剂(SSRI,n=72)的单一药物治疗。在纳入时评估 HT 和 PTSD 的存在情况,作为对样本更广泛的临床和人口统计学基线特征描述的一部分。使用耶鲁-布朗强迫症量表(YBOCS)和维度 YBOCS(DYBOCS)分别评估 OCD 症状的严重程度和类型。使用贝克抑郁量表(BDI)和贝克焦虑量表(BAI)评估抑郁和焦虑症状。两种治疗均持续 12 周。治疗反应被认为是一个分类变量[基线 YBOCS 评分降低 35%或更多,加上临床总体印象-改善评分更好(2)或好得多(1)]和连续变量(基线 YBOCS 评分的绝对值降低)。将 OCD+HT 组与无 HT 的 OCD 组以及 OCD+PTSD 组与无 PTSD 的 OCD 组进行比较。当需要时使用参数和非参数检验。共有 215 名受试者提供了 HT 和 PTSD 的相关数据。38 名受试者(整个样本的 17.67%)有阳性 HT(OCD+HT 组),22 名受试者(OCD+HT 组的 57.89%和整个样本的 10.23%)符合 DSM-IV 创伤后应激障碍的全部标准。OCD+HT 组和无 HT 的 OCD 组对 GCBT 的反应相似(第一组的 60%和第二组的 63%为应答者,p=1.00)。对于 SSRI 治疗,OCD+HT(47.4%)和无 HT(22.2%)组之间的反应差异具有边缘显著性(p=0.07)。此外,当将治疗反应视为连续变量时,OCD+PTSD 组的治疗反应大于无 PTSD 的 OCD 组(p=0.01)。第一次创伤发生的年龄对治疗反应没有影响。在 DYBOCS 测量的特定 OCD 症状维度方面,与无 PTSD 的 OCD 组相比,OCD+PTSD 组在污染性强迫观念和清洁强迫观念、收集和囤积以及其他杂项强迫观念和相关强迫观念(包括疾病担忧和精神仪式等)方面的 OCD 治疗促进了更大的减轻。OCD+PTSD 组的焦虑评分也比无 PTSD 的 OCD 组降低更多(p=0.003)。在这个非难治性 OCD 患者样本中,HT 或 PTSD 的存在与较差的治疗反应无关。出乎意料的是,与无 PTSD 的 OCD 患者相比,合并 PTSD 的 OCD 患者在特定的 OCD 症状维度上表现出更大的反应幅度。需要进一步的研究来阐明创伤和 PTSD 是否对 OCD 的发病和临床表现的影响大于对这种疾病的常规治疗,以及源于创伤的 OCD 是否构成常规治疗反应不同的 OCD 亚型。